Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.
Okuma Y, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H. Okuma Y, et al. Among authors: okamoto i. Clin Lung Cancer. 2024 Jun;25(4):336-346.e2. doi: 10.1016/j.cllc.2024.01.005. Epub 2024 Feb 2. Clin Lung Cancer. 2024. PMID: 38360497
Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
Kurata T, Matsuo K, Takada M, Kawahara M, Tsuji M, Matsubara Y, Otani N, Matsuyama S, Muraishi K, Fujita T, Ishikawa M, Koyano K, Okamoto I, Satoh T, Tamura K, Nakagawa K, Fukuoka M. Kurata T, et al. Among authors: okamoto i. J Thorac Oncol. 2006 Sep;1(7):684-91. J Thorac Oncol. 2006. PMID: 17409937 Free article. Review.
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M; West Japan Thoracic Oncology Group. Tamura K, et al. Among authors: okamoto i. Br J Cancer. 2008 Mar 11;98(5):907-14. doi: 10.1038/sj.bjc.6604249. Epub 2008 Feb 19. Br J Cancer. 2008. PMID: 18283321 Free PMC article. Clinical Trial.
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y; Lung Oncology Group in Kyushu, Japan. Ebi N, et al. Among authors: okamoto i. J Thorac Oncol. 2008 Oct;3(10):1166-71. doi: 10.1097/JTO.0b013e318186a88d. J Thorac Oncol. 2008. PMID: 18827614 Free article. Clinical Trial.
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T. Morita S, et al. Among authors: okamoto i. Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16. Clin Cancer Res. 2009. PMID: 19531624
719 results